Amaryl
(Glimepiride)ApprovedSmall molecule
SanofiGlimepiride is used to help control blood sugar levels in people with type 2 diabetes. It works by stimulating the pancreas to release more insulin.[2] Amaryl is currently approved and in use across 8 indications[4].[1]
Amaryl is one of 197 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
8
Indications
163
Total Trials
3
Active Trials
196
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
165 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Amaryl
SanofiApproved
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Routine Treatment
GSKPreclinical
Sulfonylureas
Eli LillyPreclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes52 trials
Show 49 more trials
Type 2 Diabetes Mellitus35 trials
Show 32 more trials
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin
Completed·—·Phase 4·NCT01341717·440 enrolled
Type 2 Diabetic Patients7 trials
Metformin7 trials
Show 4 more trials
Diabetes4 trials
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
Completed·—··NCT05162183·3,474 enrolled
Replication of the GRADE Diabetes Trial in Healthcare Claims Data
Completed·—··NCT05099198·6,403 enrolled
How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
Completed·—·N/A·NCT00747383·74 enrolled
Show 1 more trial
36 more indications
Diabetes Mellitus3 trials
Interaction3 trials
Efficacy and Safety3 trials
Liraglutide3 trials
Fasting Conditions3 trials
LAM2 trials
Dapagliflozin2 trials
Function2 trials
Cardiovascular2 trials
Lip2 trials
Empagliflozin2 trials
Labor2 trials
Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed Condition
Completed·—·Phase 1·NCT01053689·44 enrolled
Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition
Completed·—·Phase 1·NCT01052909·44 enrolled
Oxidative Stress1 trial
Cardiovascular Disease1 trial
Endothelial Function1 trial
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
Unknown status·—·Phase 4·NCT02301806·30 enrolled
Maturity-Onset Diabetes of the Young1 trial
IRIS1 trial
Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride
Completed·—·N/A·NCT03917940·70 enrolled
Safety and Efficacy1 trial
Efficacy1 trial
Type 2 DM1 trial
Diabetic Macular Edema1 trial
Blood Pressure1 trial
Treatment1 trial
Diabete Mellitus1 trial
Unspecified6 trials
Study of the Durability of Glycemic Control With Nateglinide
Completed·—·Phase 4·NCT00858013·88 enrolled
Regulatory
FDA Approval Timeline[5]
Nov 30, 1995
AMARYL
NDA NDA020496
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Amaryl drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Glimepiride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]